Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.28)
# 403
Out of 5,182 analysts
524
Total ratings
48.95%
Success rate
17.76%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Reiterates: Buy | $1,245 | $330.99 | +276.14% | 32 | Apr 7, 2026 | |
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | $48 → $41 | $40.95 | +0.12% | 29 | Apr 1, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $34 → $22 | $13.50 | +62.96% | 17 | Mar 31, 2026 | |
| NERV Minerva Neurosciences | Maintains: Neutral | $4 → $7 | $6.43 | +8.86% | 16 | Mar 12, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $53 → $74 | $54.26 | +36.38% | 6 | Mar 10, 2026 | |
| BHVN Biohaven | Maintains: Neutral | $11 → $10 | $9.59 | +4.28% | 18 | Mar 4, 2026 | |
| TBPH Theravance Biopharma | Maintains: Buy | $27 → $15 | $16.81 | -10.77% | 18 | Mar 4, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $33 → $34 | $27.85 | +22.08% | 24 | Mar 4, 2026 | |
| ARGX argenx SE | Maintains: Buy | $915 → $940 | $783.74 | +19.94% | 42 | Feb 27, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $34 | $23.42 | +45.18% | 5 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $0.5 | $0.29 | +75.44% | 20 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $28.62 | +22.29% | 24 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $13 | $5.22 | +149.04% | 30 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $117 | $98.51 | +18.77% | 36 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $25.55 | +48.73% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $5 | $3.31 | +51.06% | 19 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $40 | $35.40 | +12.99% | 3 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.24 | +435.71% | 18 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $2.91 | +449.83% | 27 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $33.73 | +36.38% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.14 | +122.93% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $68.85 | +71.39% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $38.62 | +109.74% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.84 | +280.43% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.22 | +710.81% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.04 | +34,515.38% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $2.07 | +383.09% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $103.21 | +76.34% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $5.26 | +256.46% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $56.14 | -67.94% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $31.26 | -74.41% | 7 | Jun 11, 2019 |
Praxis Precision Medicines
Apr 7, 2026
Reiterates: Buy
Price Target: $1,245
Current: $330.99
Upside: +276.14%
Apellis Pharmaceuticals
Apr 1, 2026
Downgrades: Neutral
Price Target: $48 → $41
Current: $40.95
Upside: +0.12%
Viridian Therapeutics
Mar 31, 2026
Maintains: Buy
Price Target: $34 → $22
Current: $13.50
Upside: +62.96%
Minerva Neurosciences
Mar 12, 2026
Maintains: Neutral
Price Target: $4 → $7
Current: $6.43
Upside: +8.86%
Xenon Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $53 → $74
Current: $54.26
Upside: +36.38%
Biohaven
Mar 4, 2026
Maintains: Neutral
Price Target: $11 → $10
Current: $9.59
Upside: +4.28%
Theravance Biopharma
Mar 4, 2026
Maintains: Buy
Price Target: $27 → $15
Current: $16.81
Upside: -10.77%
Roivant Sciences
Mar 4, 2026
Maintains: Buy
Price Target: $33 → $34
Current: $27.85
Upside: +22.08%
argenx SE
Feb 27, 2026
Maintains: Buy
Price Target: $915 → $940
Current: $783.74
Upside: +19.94%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $34
Current: $23.42
Upside: +45.18%
Feb 18, 2026
Reiterates: Neutral
Price Target: $0.5
Current: $0.29
Upside: +75.44%
Feb 10, 2026
Reiterates: Buy
Price Target: $35
Current: $28.62
Upside: +22.29%
Feb 3, 2026
Maintains: Buy
Price Target: $20 → $13
Current: $5.22
Upside: +149.04%
Jan 30, 2026
Maintains: Buy
Price Target: $80 → $117
Current: $98.51
Upside: +18.77%
Jan 9, 2026
Reiterates: Buy
Price Target: $38
Current: $25.55
Upside: +48.73%
Dec 12, 2025
Maintains: Buy
Price Target: $14 → $5
Current: $3.31
Upside: +51.06%
Dec 9, 2025
Maintains: Buy
Price Target: $34 → $40
Current: $35.40
Upside: +12.99%
Dec 2, 2025
Reiterates: Buy
Price Target: $12
Current: $2.24
Upside: +435.71%
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $2.91
Upside: +449.83%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $33.73
Upside: +36.38%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.14
Upside: +122.93%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $68.85
Upside: +71.39%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $38.62
Upside: +109.74%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.84
Upside: +280.43%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $2.22
Upside: +710.81%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $1.04
Upside: +34,515.38%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $2.07
Upside: +383.09%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $103.21
Upside: +76.34%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $5.26
Upside: +256.46%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $56.14
Upside: -67.94%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $31.26
Upside: -74.41%